vegas casino online real money

vegas casino online real money KUWAIT: The Kuwait Integrated Digital Field (KwIDF) project is reportedly ushering in a new era for the country’s oil industry, driving significant advancements in production efficiency, cost reduction, and operational effectiveness. The project, developed by Kuwait Oil Company (KOC), leverages state-of-the-art digital technologies to optimize oil field management and enhance decision-making processes, marking a pivotal shift in the way oil and gas operations are conducted in the country. Officials told state news agency KUNA that KwIDF, which integrates real-time data analysis and advanced monitoring tools, has drastically improved the speed and accuracy of production processes. By streamlining operations and minimizing the need for human intervention, KwIDF allows for greater control over oil field performance while extending the lifespan of reservoirs. Revolutionizing oil field management Hamad Al-Zaabi, Director of Innovation and Technology at KOC, described KwIDF as one of the company’s most strategic projects, offering comprehensive solutions to monitor production and resolve operational issues. “The use of cutting-edge technology to analyze well data on an hourly basis has led to significant improvements in production, with annual revenue now exceeding KD 200 million (approximately $614 million),” Al-Zaabi said. The KwIDF system continuously collects and processes data from sensors and equipment across the oil fields, providing KOC staff with instant access to critical performance reports. This real-time data allows for swift decision-making, reduces downtime, and improves overall efficiency. Additionally, the system ensures that information is easily accessible, regardless of location, saving both time and resources. Enhancing decision-making Engineer Hamad Alrashidi, Head of the Integration Team for the northern fields, emphasized how KwIDF has transformed decision-making and monitoring within KOC. “The project has revolutionized how we track performance, handle large volumes of data, and make quick decisions,” Alrashidi explained. “KwIDF now covers over 95 percent of our wells, enabling us to efficiently manage a vast amount of information and identify potential issues before they become critical.” Alrashidi also highlighted that KwIDF has played a key role in reducing operational costs, improving the quality of services, and increasing KOC’s revenue. The system’s ability to consolidate various data sources into a unified platform has also reduced the need for third-party software, leading to significant cost savings. Reducing costs The digital field project has streamlined several operational processes, particularly in the management of drilling rigs and monitoring of production centers. By optimizing the distribution of drilling rigs, KwIDF has reduced operational expenses while allowing for continuous monitoring of a larger number of wells. “In addition to cutting costs, KwIDF provides real-time alerts and detailed reports to detect anomalies quickly,” said Alrashidi. “This ensures that operations continue smoothly, even in the most remote fields.” New career opportunities Basel Alotaibi, KOC Team Leader for Reservoir Research and Technology, noted that KwIDF has opened new career opportunities, particularly in areas such as information technology, software development, and cybersecurity. These roles, previously less common in the oil sector, are now critical as the industry embraces digital transformation. “We are also enhancing our infrastructure with 4G and 5G networks, as well as cloud-based systems to support the rapid transmission and analysis of data,” Alotaibi added. “These technological upgrades have significantly improved the accuracy and reliability of operations.” KwIDF reflects KOC’s commitment to leveraging the latest technologies to enhance operational efficiency, reduce costs, and ensure sustainable oil production. By incorporating advanced solutions such as the Internet of Things (IoT), artificial intelligence (AI), and big data analytics, KOC is positioning itself at the forefront of digital innovation in the oil and gas sector. The project not only strengthens Kuwait’s position as a leader in oil production but also sets a new benchmark for the industry, ensuring greater productivity and operational sustainability for the future. — KUNADelta Board of Directors appoints Christophe Beck as newest member

A wild first season of the expanded Big 12 is down to what should be a chaotic final weekend. Through all the upsets, unexpected rises and falls, there are nine teams still in the mix to play in the conference championship game. No. 14 Arizona State and No. 17 Iowa State have the best odds, yet a multitude of scenarios could play out — 256 to be exact. There's even the possibility of an eight-team tie. It may take a mathematician to figure out which teams are in the Dec. 7 game in Arlington, Texas — even for the ones who win. Star power Travis Hunter, Colorado. The Buffaloes' two-way star has excelled on both sides of the field, making him one of the favorites to win the Heisman Trophy. Cam Skattebo, Arizona State. The senior running back can do a little of everything, but excels at punishing would-be tacklers. He's one of the nation's leaders in yards after contact and the focal point of the Sun Devils' offense. People are also reading... Shadeur Sanders, Colorado. If it weren't for Hunter, Sanders might be the Heisman favorite. The son of coach Deion Sanders, Shedeur is fifth nationally with 3,488 yards passing and has been a big part of the Buffaloes' turnaround. DJ Giddens, Kansas State. The Wildcats' running back is one of the nation's most versatile players. He is ninth nationally with 1,271 rushing yards and has added 21 receptions for 258 yards. Tetairoa McMillan, Arizona. The Wildcats have struggled this season, but McMillan has not. He is third nationally with 1,251 receiving yards with seven touchdowns on 78 catches. Jacob Rodriguez, Texas Tech. The Red Raiders' junior linebacker leads the Big 12 with 68 tackles, averaging 10.2 per game. He also has four sacks. Brendan Mott, Kansas State. He's a menace to opposing quarterbacks, leading the Big 12 with 8 1/2 sacks. Going bowling The Big 12 has nine teams already bowl eligible and two more a win away. The winner of the Big 12 championship game will be in the mix for a College Football Playoff spot. Arizona State, Iowa State, No. 19 BYU, Colorado, Kansas State, Baylor, TCU, Texas Tech and West Virginia have already clinched bowl berths. Kansas and Cincinnati can get into the postseason with wins this weekend. Hot seats Gus Malzahn, UCF. Despite successes in recruiting, the Knights are 10-14 in two seasons since moving to the Big 12. Maybe not enough to get shown the door this year, but another mediocre season could lead UCF to make a change. Kyle Whittingham, Utah. Whittingham was one of the Pac-12's best coaches, leading the Utes to consecutive conference titles. Utah was expected to contend for the Big 12 title its first year in the league, but enters the final weekend 1-7 in conference play, which could push Whittingham toward retirement since it's doubtful he'd be fired. Neal Brown, West Virginia. The Mountaineers' coach was in a precarious spot at the end of last season and West Virginia hasn't lived up to expectations this season. The Mountaineers are eligible to go to a bowl game for the second straight season, but Brown could be on the hot seat even after signing a contract extension before the season. Youth movement Josiah Trotter, West Virginia. The redshirt freshman is the latest Trotter to have success at the linebacker position, following the footsteps of his father, former Philadelphia Eagles player Jeremiah Trotter, and brother Jeremiah Trotter Jr., a current Eagles linebacker. Sam Leavitt, Arizona State. The Michigan State transfer has been just what the Sun Devils' needed: an agile quarterback who extends plays with his legs and rarely makes bad decisions. Bryson Washington, Baylor. The Bears' running back has rushed for 812 yards — 196 against TCU — and 10 TDs. Recruiting watch TCU has the Big 12's highest rated 2025 recruiting class with six four-star players among 26 commitments, according to the 247 Sports composite. Receiver Terry Shelton of Carrollton, Texas, is the highest-rated recruit at 71st nationally. Baylor is next with five five-star players among its 20 commitments, including running back Michael Turner, rated 13th at his position out of North Richland Hills, Texas. Texas Tech is ranked seventh in the Big 12, but has four four-star recruits. Get local news delivered to your inbox!

The year in money: inflation eased, optimism ticked upwardAPA Corp. stock outperforms competitors despite losses on the day

Dry AMD Market Size in the 7MM was ~ USD 1,300 million in 2023, estimated DelveInsight 11-25-2024 11:14 PM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Dry AMD Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Dry AMD, historical and forecasted epidemiology as well as the Dry AMD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover Key Insights into the Dry AMD Market with DelveInsight's In-Depth Report @ Dry AMD Market Size [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from the Dry AMD Market Report * In November 2024:- Stealth BioTherapeutics Inc.- A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD). * In November 2024:- Cognition Therapeutics- This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD. * The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023. * Among the 7MM, the US accounted for the highest prevalent cases of dry AMD in 2023, with around 20,970,000 cases; these cases are expected to increase during the forecast period. * Several researchers reported a declining prevalence of late AMD in the United States when comparing data from the 2000s with data gathered in previous decades. * In 2023, the geographical atrophy accounted for nearly 955,900 cases in EU4 and the UK. * According to the estimates, in Japan, it is observed that age-specific cases of geographic atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023. * The leading Dry Age-Related Macular Degeneration Companies such as Alkeus Pharmaceuticals, Novartis, Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics , and others. * Promising Dry Age-Related Macular Degeneration Therapies such as Iptacopan (LNP023), ALK-001, RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104 , and others. Stay ahead in the Dry AMD Therapeutics Market with DelveInsight's Strategic Report @ Dry AMD Market Outlook [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Dry AMD Epidemiology Segmentation in the 7MM * total prevalent cases of AMD, * stage-specific prevalent cases of AMD, * total prevalent cases of geographic atrophy, * total prevalent cases of dry AMD, * total diagnosed prevalent cases of dry AMD, * age-specific cases of early and intermediate AMD, * age-specific cases of geographic atrophy, * geographic atrophy cases by visual impairment Download the report to understand which factors are driving Dry AMD epidemiology trends @ Dry AMD Prevalence [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Marketed Dry Age-related Macular Degeneration Drugs IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio IZERVAY, also known as avacincaptad pegol is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. By inhibiting the formation of complement system terminal fragments, IZERVAY may decrease the activation of inflammasomes and the formation of membrane attack complexes (MAC), which occur at the end of the complement cascade. In August 2023, the US FDA approved IZERVAY for the treatment of geographic atrophy secondary to AMD. Concurrently, Astellas Pharma announced that the European Medicines Agency (EMA) has accepted Iveric Bio's MAA for avacincaptad pegol for the treatment of geographic atrophy secondary to AMD. SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals SYFOVRE is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. The company is evaluating pegcetacoplan in several clinical studies, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), complement-dependent nephropathies (CDN). SYFOVRE is the first and only approved therapy for geographic atrophy secondary to AMD. In January 2024, the CHMP of the EMA adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to AMD. Emerging Dry Age-related Macular Degeneration Drugs * Iptacopan (LNP023): Novartis Novartis Pharmaceuticals is developing Iptacopan, an oral small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, FB inhibitor LNP023 binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as intermediate age-related macular degeneration (iAMD), C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), etc. Recently, in December 2023, the US FDA approved FABHALTA (ipatocan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH) (Novartis, 2023). Currently, the company is investigating iptacopan in the Phase II trial (NCT05230537) for the treatment of patients with early and intermediate age-related macular degeneration. * ALK-001: Alkeus Pharmaceuticals Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA. Get In-Depth Knowledge on Dry AMD Market Trends and Forecasts with DelveInsight @ Dry AMD Treatment Market [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Dry AMD Market Outlook Geographic atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward GA. Enhancing comprehension of the pathophysiology of geographic atrophy resulting from dry AMD can benefit patients, optometrists, and ophthalmologists alike. This improved understanding could lead to more accurate identification and diagnosis of patients, potentially lessening the burden of the disease and extending their visual function over time. Dry AMD Drugs Market Integrin inhibitor have been effective in several preclinical models, and promising results have been reported thus far from clinical trials. Indeed, most of the current avSs3 clinical investigations centre on treating eye diseases (age-related macular degeneration (AMD) using topically dosed or intravitreally injected small molecules and peptides, although these molecules also inhibit other av integrins and/or a5Ss1 to varying degrees. The molecules that have progressed the furthest in the clinic are risuteganib (Luminate, Allegro Ophthalmics). It is a small peptide integrin regulator protecting cells of the human RPE against dysfunction related to oxidative stress. With age, decreased mitochondrial oxidative phosphorylation increases the generation of reactive oxygen species and decreased metabolic activity, thus negatively affecting cellular bioenergetics and mitochondrial functioning. It is also known that RPE mitochondrial dysfunction contributes to the oxidative stress causing AMD. Unlock Strategic Insights with DelveInsight's Comprehensive Dry AMD Market Report @ Dry AMD Market Drivers and Barriers [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Scope of the Dry AMD Market Report * Coverage- 7MM * Dry AMD Companies- Alkeus Pharmaceuticals, Novartis, Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others. * Dry Age-Related Macular Degeneration Therapies- Iptacopan (LNP023), ALK-001, RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others. * Dry AMD Therapeutic Assessment: Dry AMD Current marketed and Lipodystrophy Emerging Therapies * Dry AMD Market Dynamics: Dry AMD Market drivers and Dry AMD Market Barriers Table of Content 1. Key Insights 2. Executive Summary 3. Dry Age-Related Macular Degeneration Competitive Intelligence Analysis 4. Dry Age-Related Macular Degeneration Market Overview at a Glance 5. Dry Age-Related Macular Degeneration Disease Background and Overview 6. Dry Age-Related Macular Degeneration Patient Journey 7. Dry Age-Related Macular Degeneration Epidemiology and Patient Population 8. Dry Age-Related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices 9. Dry Age-Related Macular Degeneration Unmet Needs 10. Key Endpoints of Dry Age-Related Macular Degeneration Treatment 11. Dry Age-Related Macular Degeneration Marketed Products 12. Dry Age-Related Macular Degeneration Emerging Therapies 13. Dry Age-Related Macular Degeneration Seven Major Market Analysis 14. Attribute Analysis 15. Dry Age-Related Macular Degeneration Market Outlook (7 major markets) 16. Dry Age-Related Macular Degeneration Access and Reimbursement Overview 17. KOL Views on the Dry Age-Related Macular Degeneration Market 18. Dry Age-Related Macular Degeneration Market Drivers 19. Dry Age-Related Macular Degeneration Market Barriers 20. Appendix 21. DelveInsight Capabilities About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=dry-amd-market-size-in-the-7mm-was-usd-1300-million-in-2023-estimated-delveinsight ] Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/in-licensing-opportunity This release was published on openPR.

Wild first season in expanded Big 12 comes down to final weekendShares of off-price department store retailer Burlington Stores Inc ($BURL) were in the spotlight after the firm reported upbeat third-quarter earnings. Total revenue rose 10.5% year-over-year (YoY) to $2.53 billion during the quarter, but fell short of a Wall Street estimate of $2.55 billion. Adjusted earnings per share (EPS) came in at $1.55 compared to an estimate of $1.54. Net income rose 86% YoY to $90.6 million during the quarter. CEO Michael O’Sullivan said although the third quarter comp trend started out very strongly, but then warmer temperatures from mid-September onwards slowed the sales momentum. “Cold Weather categories represent about 15% of sales in the third quarter. Excluding these categories, our comp growth in the third quarter was 4%, which is consistent with the trend that we have seen in our business since March. We are very encouraged by this underlying comp sales trend,” O’Sullivan said. For the full fiscal-year 2024, the company expects total sales to increase in the range of 9% to 10% on top of the 10% increase for the 52-weeks ended Jan. 27, 2024. Adjusted EPS is expected in the range of $7.76 to $7.96, which excludes $0.11, net of tax, of expenses associated with the acquired Bed Bath & Beyond leases. Following the earnings announcement, retail sentiment on Stocktwits jumped into the ‘extremely bullish’ territory (77/100) from ‘extremely bearish’ a day ago, accompanied by extremely high retail chatter that hit a one-year high. Shares of Burlington Stores were down nearly 1% on Tuesday. The stock has gained over 48% on a year-to-date basis, significantly outperforming the benchmark U.S. indices. For updates and corrections email newsroom[at]stocktwits[dot]com.<

Lil Wayne, GloRilla, Camila Cabello to perform at College Football National ChampionshipAnalysis: Win or lose at UNC, Belichick's NFL legacy cementedTrump’s team is delaying transition agreements. What does it mean for security checks and governing?

Wild first season in expanded Big 12 comes down to final weekend

John Harbaugh Gives Cryptic Answer About Diontae Johnson's Future with Ravens

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV). Shareholders who purchased shares of EVLV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/evolv-technologies-holdings-inc-loss-submission-form-2/?id=113434&from=3 CLASS PERIOD: August 19, 2022 to October 30, 2024 ALLEGATIONS: According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Company’s financial statements prepared for the periods between Q2 2022 through Q2 2024 contained material misstatements relating to improper revenue recognition and other reported metrics that are a function of revenue. In truth, Evolv’s sales, including sales to one of its largest channel partners, were subject to extra-contractual terms and conditions not shared with the Company’s accounting personnel, distorting the Company’s reported revenue and other metrics that are a function of revenue during the Class Period. What’s more, far from the Company’s touted “growing momentum” and “continued traction” with channel partners, the Company’s personnel was engaged in misconduct concerning sales to one of the Company’s largest channel partners. DEADLINE: December 31, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/evolv-technologies-holdings-inc-loss-submission-form-2/?id=113434&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EVLV during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 31, 2024. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (646) 453-8903

Mortuary Equipment Market to Experience Robust Growth, Projected to Reach USD 1,807.0 Million by 2033 at a 5.8% of CAGR 12-13-2024 07:39 PM CET | Health & Medicine Press release from: Future Market Insights Mortuary Equipment Market The global mortuary equipment market is expected to witness strong growth, with an average compound annual growth rate (CAGR) of 5.8% between 2023 and 2033. Valued at USD 1,025.8 million in 2023, the market is projected to reach USD 1,807.0 million by 2033. This growth is driven by several factors, including an increase in mortality rates, the rising geriatric population, and the expanding healthcare infrastructure, including morgues and hospitals. The demand for mortuary equipment has been bolstered by a combination of factors, including an aging population and the growing prevalence of chronic diseases. These developments are leading to higher mortality rates, which in turn are increasing the need for advanced mortuary equipment to manage and process bodies efficiently. Additionally, advancements in technology, particularly automation in mortuary procedures like embalming, autopsy, and storage, are contributing to the rising demand for specialized equipment in this sector. Technologically advanced mortuary equipment is reducing processing times and improving convenience for professionals in the field. The integration of automated solutions into body embalming, autopsy, storage, and transportation procedures has streamlined workflows and increased operational efficiency in morgues and hospitals. As a result, the industry is seeing a rise in the adoption of these advanced solutions, which not only enhance the effectiveness of mortuary operations but also address the growing need for high-quality, reliable equipment. As the global mortality rate continues to rise, driven by an increasing elderly population and the prevalence of chronic diseases, the demand for mortuary equipment is expected to grow steadily. The continued development and adoption of innovative technologies in this field will further fuel the market's expansion, presenting significant opportunities for key players in the industry. Request a Sample of this Report Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-14975 Key Takeaways: The mortuary equipment market is projected to grow from USD 1.03 billion in 2023 to USD 1.81 billion by 2033, at a CAGR of 5.8%. Key drivers include an aging population, increased chronic diseases, and expanding healthcare facilities. Automation and advanced technologies in mortuary procedures are boosting market demand. The market's growth is expected to continue as mortality rates rise and new innovations emerge in mortuary equipment. Key Drivers of Market Growth Increasing Mortality Rates: The demand for mortuary equipment is rising due to a combination of factors such as a decreasing lifespan, the growing geriatric population, and the prevalence of chronic diseases. These factors contribute to higher mortality rates, thereby increasing the need for effective mortuary services and equipment. Expansion of Healthcare Facilities: The establishment and expansion of healthcare units, including morgues and hospitals, are driving the demand for mortuary equipment. As healthcare infrastructure improves, there is a corresponding need for advanced equipment to handle deceased bodies safely and efficiently. Automation in Mortuary Procedures: The penetration of automation in various mortuary processes-such as body embalming, autopsy, storage, and transportation-enhances efficiency and reduces processing times. This trend is contributing to increased demand for technologically advanced mortuary equipment. Technological Advancements: Innovations in mortuary equipment are improving the convenience and effectiveness of operations for professionals in the field. Advanced technologies are being integrated into equipment to streamline processes and ensure better handling of deceased bodies. Research and Development Initiatives: Increased investments in research and development programs related to mortuary services are leading to enhanced product offerings and improved operational efficiencies within the industry. Focus on Infection Control: With heightened awareness around infection control, especially post-pandemic, there is an increased emphasis on using high-quality mortuary equipment that minimizes contamination risks during handling and storage. How is the Competition in the Mortuary Equipment Market? Emerging trends in the mortuary equipment market are shaping the market's competitive analysis. The companies have increased their manufacturing units as covid-19 has triggered the demand for mortuary equipment. These manufacturing units have been set up to fill that demand. Governments integrating with death care service providers and mortuary equipment systems to tackle the high COVID-19 bodies that need special embalming and storage has also changed the competitor's approach to R&D. Some key players shaping the mortuary equipment market are SM Scientific Instruments Pvt. Ltd., KUGEL Medical GmbH & Co. KG, Leec Ltd, Thermo Fisher Scientific, Inc., and Mortech Manufacturing Company, Inc. Recent Developments in the Mortuary Equipment Market SM Scientific has completed its 50 years of service and has added new equipment like Body Display Cabinets, Organ Weighing Scale, and Evidence Drying Cabinet. This has pushed the demand for mortuary equipment in new regional spaces. Leec Ltd has introduced its set of mortuary equipment like body storage, post-mortem spaces, dissecting, and organ weight calculator, pushing the demand for mortuary equipment in the country. Key Players SM Scientific Instruments Pvt. Ltd. KUGEL medical GmbH & Co. KG Leec Ltd Thermo Fisher Scientific, Inc. Mortech Manufacturing Company, Inc. Key Segments By Product: Trolleys Refrigeration Units Autopsy Platforms and Equipment Embalming Workstation Dissection Table Other Accessories By Region: Latin America Europe Asia Pacific Middle East and Africa Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain: Nucleic Acid Testing Industry - https://www.futuremarketinsights.com/reports/nucleic-acid-testing-market Neurological Biomarkers Industry - https://www.futuremarketinsights.com/reports/neurological-biomarkers-market Ultrasound Conductivity Gels Industry - https://www.futuremarketinsights.com/reports/ultrasound-conductivity-gels-market About Future Market Insights (FMI) Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Contact Us: Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-347-918-3531 For Sales Enquiries: sales@futuremarketinsights.com Website: https://www.futuremarketinsights.com LinkedIn| Twitter| Blogs | YouTube This release was published on openPR.Kentucky will aim to improve upon its best start in seven seasons when it hosts Western Kentucky on Tuesday night in Lexington, Ky., in the final game of the BBN Invitational. The Wildcats (5-0) are ranked No. 8 in the latest Associated Press poll and are setting impressive offensive milestones even for a program as tradition-rich as Kentucky, which includes eight national championships. The Wildcats have scored 97 or more points in their first four home games for the first time in program history and eclipsed the 100-point mark in three of those games. Their lone trip out of state was a solid 77-72 victory over Duke in a matchup of top-10 teams in Atlanta. Kentucky has also made at least 10 three-pointers in each of its first five games of a season for the first time ever. "I think Kentucky attracts good people," Kentucky coach Mark Pope said after the Wildcats' 108-59 win over Jackson State on Friday. "It's the one place in all college basketball where you represent just a fanbase in a different, unique way." Otega Oweh and Koby Brea have led the Wildcats' early scoring outburst. Oweh, who is averaging 16.2 points per game, had 21 points on 8-for-12 shooting against Jackson State. "He gets us off to unbelievable starts every night," Pope told reporters after that game. "He's probably been our most consistent guy in games." Brea, who scored 22 points against Jackson State and is averaging 16.0 points per game, is leading the nation in 3-point accuracy at 74.1 percent. As a team, the Wildcats are shooting 42.3 percent from beyond the arc. And the few times they miss, Amari Williams has been doing the dirty work on the glass, averaging 10.8 boards in addition to 9.6 points per game. Kentucky faces a different challenge than it's had to contend with so far in the Hilltoppers (3-2), who have won three in a row after losing their first two games to Wichita State and Grand Canyon. Their up-tempo play hasn't exactly resulted in great offensive output, but in the Hilltoppers' 79-62 win over Jackson State on Wednesday, they shot 45.2 percent from 3-point range (14 for 31). "I was happy to see a lot of different guys contribute tonight and, hopefully, get their feet under them a little bit and get some confidence," said Western Kentucky coach Hank Plona, who is in his first season as head coach. "Obviously, Tuesday will be quite a test and challenge for us and we'll need them to be at their absolute best." Western Kentucky has an experienced group, which returned mostly intact from last season. The team is led by Conference USA first-team selection Don McHenry, who is leading the team with 17.2 points and 2.2 steals per game. McHenry is one of four Hilltoppers with scoring averages in double figures. Julius Thedford (11.4 points per game) and Babacar Faye (15.0) are each shooting 40 percent or better from 3-point range. Western Kentucky also figures to challenge the Wildcats on the boards as it enters the game ranked in the top 25 in defensive rebounding (30.4 per game). Faye leads the Hilltoppers in that department, averaging 7.8 rebounds per game and figures to battle Williams inside. "We're not the biggest team in the world, but our depth and our quickness are our strengths," Plona said. --Field Level Media

( MENAFN - Newsfile Corp) Toronto, Ontario--(Newsfile Corp. - December 13, 2024) - Impact Development Group Inc. ( TSXV: IMPT ) (" Impact ", or the " Company "), a leading Panamanian developer of affordable housing solutions, would like to provide updates on its activities in the Republic of Panama in connection with the Housing Solidarity Subsidy (the " Program ") which governs subsidies issued in connection with homes built for social interest purposes. On July 1st, 2024 the Ministry of Housing and Land Management (" MIVIOT ") commenced a comprehensive review of the Program and other subsidies issued in connection with homes built for social interest purposes. MIVIOT has since paused the approval of subsidies in connection with the building and delivery of new homes, and the Program has lapsed effective June 30, 2024. Since August, MIVIOT has maintained a working group with housing developers across the country, generating several proposals for alternatives to the Program, all of which remain under review and have not yet been implemented. There has been no indication from the government of Panama that the Program will be resumed. MIVIOT is currently continuing to honor payments for homes that received certification pursuant to the Program prior to June 30, 2024. As of the date of this news release, the Company has a total of 125 homes that are pending subsidy payments or certification under the Program and 171 homes in inventory, either completed or under construction, that have not yet received MIVIOT subsidy certification under the Program. It is unclear if 171 of those homes will ever receive MIVIOT certification to receive subsidies pursuant to the Program. Given the current circumstances, the Company has been evaluating its strategic objectives as they relate to its operations in Panama to focus on the delivery of existing inventory, pause all new development, and consider opportunities to diversify the Company's business. In alignment with this proposed strategy, the Company recently completed the acquisition of Fusion Software, LLC (" Fusion Software "), a leading US-based platform for managing low-income housing tax credit portfolios for housing developers, syndicators and investors. This acquisition marks a significant milestone in Impact's commitment to affordable housing solutions and expands the Company's capabilities in other markets. For further details regarding the acquisition of Fusion Software, please see the Company's news release dated October 25, 2024. To continue growing and diversifying the business, the Company is evaluating initiatives peripheral to building affordable homes under the Program. This includes evaluating options to expand into new residential or commercial development activities outside of the Program. Any new initiative pursued by Impact will seek to leverage its core competencies developed over the 11 years of its operational success in Panama. Other strategies currently under evaluation by the Company's management include geographic expansion to adjacent markets with similar programs and the diversification into new technology-enabled revenue streams in affordable housing. Any material change to the business following the conclusion of the Company's evaluations will be conducted in accordance with applicable securities laws and regulations of the TSX Venture Exchange. ABOUT IMPACT Impact is a Panamanian based real estate developer that provides affordable housing solutions to Panama's growing middle-class and has historically been supported by longstanding subsidized government programs in Panama. The vision of the Company is effectuated by a vertically integrated model which coordinates all services necessary to develop high-quality residential and commercial buildings, including land acquisition, financing, architectural, engineering, off-site manufacturing, general contracting, property management, and administration. Impact also operates, through its subsidiary, Fusion Software LLC, an innovative software platform designed to streamline the administration of low-income housing tax credits for asset managers, developers and syndicators. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact: Tom Wenz, Director and CEO Phone: + 1 (702) 329-8038 Email: ... FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements" that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company's business activities in Panama; the Company's plans to continue growing and diversifying the business; the Company's 125 homes pending disbursement of the subsidy or approvals from the Program; and the Company's plans to evaluate its business in light of the recent changes to the Program. The forward-looking statements, while considered reasonable by the Company, are inherently based upon assumptions that are subject to significant risks and uncertainties, including, but not limited to, the Company being able to carry out its business plan as contemplated; the Company's ability to grow and diversify its business; the Company's 125 homes pending receipt of disbursements of subsidies or approvals under the Program; and the Company's plans to evaluate its business in light of recent changes to the Program. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, they can give no assurances that the expectations of any forward-looking statements will prove to be correct. Such statements and information reflect the current view of the Company. Risks and uncertainties exist that may cause actual results to differ materially from those indicated or implied in the forward-looking statements and information. Such factors include, among others: the limited business history of the Company; the Company's reliance on key management; risks related to the Company's growth strategy, including that previous and future acquisitions do not meet expectations or potential acquisitions cannot be completed; the Company's 125 homes not receiving disbursements of subsidies or approvals under the Program; the business of the Company being subject to broader economic and political factors, including but not limited to decisions made by the government of Panama; disruptions or changes in the credit or security markets; financial results of the Company's operations; unanticipated costs and expenses; and general market and industry conditions. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws. To view the source version of this press release, please visit SOURCE: Impact Development Group Inc. MENAFN13122024004218003983ID1108991791 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.A judge on Monday granted a request by prosecutors to dismiss the election subversion case against Donald Trump because of a Justice Department policy of not prosecuting a sitting president. Judge Tanya Chutkan agreed to the request by Special Counsel Jack Smith to dismiss the case against the president-elect "without prejudice," meaning it could potentially be revived after Trump leaves the White House four years from now. "Dismissal without prejudice is appropriate here," Chutkan said, adding in the ruling that "the immunity afforded to a sitting President is temporary, expiring when they leave office." Trump, 78, was accused of conspiring to overturn the results of the 2020 election he lost to Joe Biden and removing large quantities of top secret documents after leaving the White House, but the cases never came to trial. Smith also moved on Monday to drop his appeal of the dismissal of the documents case filed against the former president in Florida. That case was tossed out earlier this year by a Trump-appointed judge on the grounds that Smith was unlawfully appointed. The special counsel paused the election interference case and the documents case this month after Trump defeated Vice President Kamala Harris in the November 5 presidential election. Smith cited the long-standing Justice Department policy of not indicting or prosecuting a sitting president in his motions to have the cases dismissed. "The Government's position on the merits of the defendant's prosecution has not changed," Smith said in the filing with Chutkan. "But the circumstances have." "It has long been the position of the Department of Justice that the United States Constitution forbids the federal indictment and subsequent criminal prosecution of a sitting President," Smith said. "As a result this prosecution must be dismissed before the defendant is inaugurated." In a separate filing, Smith said he was withdrawing his appeal of the dismissal of the classified documents case against Trump but pursuing the case against his two co-defendants, Trump valet Walt Nauta and Mar-a-Lago property manager Carlos De Oliveira. Trump, in a post on Truth Social, said the cases were "empty and lawless, and should never have been brought." "Over $100 Million Dollars of Taxpayer Dollars has been wasted in the Democrat Party's fight against their Political Opponent, ME," he said. "Nothing like this has ever happened in our Country before." Trump was accused of conspiracy to defraud the United States and conspiracy to obstruct an official proceeding -- the session of Congress called to certify Biden's win, which was violently attacked on January 6, 2021 by a mob of the then-president's supporters. Trump was also accused of seeking to disenfranchise US voters with his false claims that he won the 2020 election. The former and incoming president also faces two state cases -- in New York and Georgia. He was convicted in New York in May of 34 counts of falsifying business records to cover up a hush money payment to porn star Stormy Daniels on the eve of the 2016 election to stop her from revealing an alleged 2006 sexual encounter. However, Judge Juan Merchan has postponed sentencing while he considers a request from Trump's lawyers that the conviction be thrown out in light of the Supreme Court ruling in July that an ex-president has broad immunity from prosecution. In Georgia, Trump faces racketeering charges over his efforts to subvert the 2020 election results in the southern state, but that case will likely be frozen while he is in office. cl/smsWOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the Accelerated Approval pathway. The Company also announced that the FDA has granted Breakthrough Therapy designation to RP1 in combination with nivolumab in the same setting. Breakthrough Therapy designation is intended to expedite the development and review of therapies for serious diseases when preliminary clinical evidence indicates that the therapy may provide substantial improvement over existing available therapies on one or more clinically significant endpoints. This Breakthrough Therapy designation is based on the safety and clinical activity observed in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial. “Today is an important milestone for Replimune and for the melanoma community as we are one step closer to having another potential treatment available for patients who have limited options after progressing on anti-PD1 containing regimens,” said Sushil Patel, Ph.D., CEO of Replimune. The confirmatory Phase 3 IGNYTE-3 trial of RP1 in combination with nivolumab in advanced melanoma patients who have progressed on anti-PD1 and anti-CTLA-4 therapy, or who are not candidates for anti-CTLA-4 treatment is currently enrolling patients. For more information, visit https://replimune.com/clinical-trials/ignyte-3/ . About RP1 RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF, intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com . Forward Looking Statements This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our belief regarding the effect that the breakthrough designation will have on the timing and development of RP1 and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. Investor Inquiries Chris Brinzey ICR Healthcare 339.970.2843 chris.brinzey@westwicke.com Media Inquiries Arleen Goldenberg Replimune 917.548.1582 media@replimune.comDolphins coach Mike McDaniel says he was surprised by reports of Shaq Barrett's unretirement plan

Nasdaq, S&P 500 close at record highs Monday with tech-related sharesAmbala, Jind DCs seek immediate medical assistance for Dallewal

Minnesota's Cannabis License Lottery Faces Legal Delays Over Rejections DisputeMeet the start-up working to save newborn babies and democratize pregnancy care

Appotronics Highlights Role of Laser Technology in Automotive Industry at Prestigious US Trade ConferenceRavens QB Jackson leads first NFL Pro Bowl fan voting results

Syracuse and Georgetown meet for the 100th time Saturday when the Orange host the Hoyas in the latest installment of their classic rivalry. As former Big East Conference rivals, Syracuse and Georgetown have staged many memorable contests over the decades with the Orange holding a 54-45 all-time advantage. The teams still meet annually despite the Orange now playing in the Atlantic Coast Conference. Syracuse has won five of the last seven meetings, including a 12-point triumph in Washington D.C. last December. "It definitely felt like a Big East game," Hoyas coach Ed Cooley said after last season's contest. This time around, Georgetown (7-2) is coming off a 73-60 loss to West Virginia in which the team shot under 38 percent from the floor and committed 14 turnovers. "When the ball has music, when the ball is singing, unbelievable music happens," Cooley said. "The music is the play. The music is body movement and screening an open shot. We didn't have good music today." Thomas Sorber is the team's leading scorer at 15.4 points per game, although the freshman has failed to reach that average in six of the last seven games. Syracuse (5-4), meanwhile, is coming off a 102-85 win over Albany despite the absence of leading scorer J.J. Starling (19.8 points), who is out indefinitely with a hand injury. In his stead, freshman Donnie Freeman supplied 24 points on 10-of-13 shooting despite playing just 23 minutes due to an illness. "Whatever (illness) he has, he needs to keep that, if he can keep playing like, whatever he was feeling," Orange coach Adrian Autry joked. Syracuse will be looking for more success from 3-point range after hitting 6-of-15 (40 percent) against Albany. In their previous game -- a five-point loss to Notre Dame -- the Orange failed to make a 3-pointer for the first time in more than a decade. No Syracuse player has made more than 11 3-pointers this season -- and even that player (Chris Bell) is only shooting 25 percent from long distance. --Field Level MediaWhat the upcoming holiday GST relief will mean for consumers